Inhibitory effect of rosuvastatin on SARS-CoV-2

Based on in silico studies statins could be efficient SARS-CoV-2 Mpro inhibitors, especially rosuvastatin. It has been also showed that rosuvastatin can significantly decrease the rate of deep vein thrombosis (JUPITER trial), and that it can improve lung pathological changes by decreasing T helper cells Th2 and Th17-mediated cytokines. Therefore, rosuvastatin might be an useful adjunct therapy in patients with COVID-19, especially in those who already have an indication for statin use (homozygous familial hypercholesterolemia, hyperlipidemia, mixed dyslipidemia, primary dysbetalipoproteinemia, hypertriglyceridemia, prevention of cardiovascular disease).